A Drug Interaction Study of ACH-0145228

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 22, 2019

Primary Completion Date

April 16, 2020

Study Completion Date

April 16, 2020

Conditions
Healthy
Interventions
DRUG

ACH-0145228

ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.

DRUG

Midazolam

Midazolam was dosed at 2 mg (1 milliliter \[mL\] of a 2 mg/mL syrup).

DRUG

Digoxin

Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.

DRUG

Itraconazole

Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).

Trial Locations (1)

85283

Clinical Study Site, Tempe

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

collaborator

Celerion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY